Trial intelligence / Profile preview

Phase III randomized double-blind study of ramucirumab (IMC-1121B) plus docetaxel versus placebo plus docetaxel in previously untreated HER2-negative locally recurrent unresectable or metastatic breast cancer

2008-001727-65Phase 3Completed

Sponsor

Eli Lilly and Company

Start

Nov 2008

Modality

Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1